METAOD002: A Phase IIa (double-blind, placebo-controlled 4 4 Latin Square design) safety study with single doses (25, 50 and 100 g/kg AOD9604) administered intravenously to 23 healthy clinically obese males presenting with a BMI 35 kg/m 2
Some had no published studies in humans, and there were safety concerns like the potential to encourage cancer growth or trigger a massive immune response
[DOI] [PMC free article] [PubMed] [Google Scholar] 142.Back A.L., Freeman-Young T.K., Morgan L., Sethi T., Baker K.K., Myers S., McGregor B.A., Harvey K., Tai M., Kollefrath A., et al
Lower cost per mg Long-term workflow efficiency Suitable for high-volume research Optimised for repeat laboratory use How does 100mg compare to 50mg
Integration With Other Compounds A well-structured stack and cycle plan can match 5-Amino-1MQ with complementary compounds for specific goals: Aggressive Fat Loss: Pair with CJC-1295 vs Ipamorelin and AOD-9604 during short, intense cut phases
Tesamorelin tackles it head-on
